Last reviewed · How we verify
Emollient (moisturizer)
An emollient moisturizer works by forming an occlusive barrier on the skin surface to reduce transepidermal water loss and restore skin hydration.
An emollient moisturizer works by forming an occlusive barrier on the skin surface to reduce transepidermal water loss and restore skin hydration. Used for Dry skin conditions, Xerosis, Skin barrier dysfunction.
At a glance
| Generic name | Emollient (moisturizer) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Emollient/Moisturizer |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Emollients are lipophilic substances that penetrate the stratum corneum and create a hydrophobic film on the skin, preventing water evaporation and improving skin barrier function. They soften and smooth the skin by filling in gaps between desquamated cells and restoring the skin's natural moisture content. This mechanism is particularly useful in treating dry skin conditions and maintaining skin integrity.
Approved indications
- Dry skin conditions
- Xerosis
- Skin barrier dysfunction
Common side effects
- Local skin irritation
- Contact dermatitis
- Folliculitis
Key clinical trials
- Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (PHASE4)
- Efficacy of Dipotassium Glycyrrhizinate Emollients in the Maintenance Treatment of Adult Atopic Dermatitis (NA)
- Emollient 'Plus' vs Urea 10% for Mild-Moderate Atopic Dermatitis (NA)
- Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
- Evaluating the Efficacy and Safety of Cleanser, Serum, and Sunscreen Products for Facial Redness. (PHASE3)
- Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (PHASE2)
- Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin (NA)
- Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emollient (moisturizer) CI brief — competitive landscape report
- Emollient (moisturizer) updates RSS · CI watch RSS
- Sanofi portfolio CI